Sensitivity and specificity of Epstein-Barr virus IgA titer in the diagnosis of nasopharyngeal carcinoma: A three-year institutional review

Head and Neck

Volumn 26, Issue 7, 2004, Pages 598-602

  Tsang, Raymond K Y ^a   Vlantis, Alexander C ^a   Ho, Fticky W K ^a   Tam, John S L ^a   To, K F ^a   Van Hasselt, C Andrew ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

EBV; EBV IgA; Nasopharyngeal carcinoma; Nasopharyngeal carcinoma screening; Sensitivity

Indexed keywords

IMMUNOGLOBULIN A; VIRUS CAPSID ANTIGEN;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; CALCULATION; CANCER DIAGNOSIS; CANCER SCREENING; CONTROLLED STUDY; ENDEMIC DISEASE; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CANCER; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID; CAPSID PROTEINS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN A; NASOPHARYNGEAL DISEASES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 3042826423     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.20022     Document Type: Review

References (13)

1. Hong Kong Cancer Registry; 1996.
2. Huang DP, Ho JHC, Henle W, Henle G. Demonstration of Epstein-Barr virus-associated nuclear antigen in nasopharyngeal carcinoma cells from fresh biopsies. J Int Cancer 1974;14:580-588.
3. Old LJ, Boyes EA, Oettgen HK, et al. Precipitating anti-body in human serum to an antigen present in cultured Burkitt's lymphoma cells. Proc Natl Acad Sci U S A 1966;56:1699-1704.
4. Henle W, Henle G, Ho HC, et al. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J Natl Cancer Inst 1970;44:225-231.
5. Tam JS. Epstein-Barr virus serological markers. In: van Hasselt CA, Gibb AG, editors. Nasopharyngeal carcinoma. 2nd edition. Hong Kong: The Chinese University Press; 1999. p 165-168.
6. Ho HC, Ng MH, Kwan HC, Chau JC. Epstein-Barr virus-specific IgA and IgG serum antibodies in nasopharyngeal carcinoma. Br J Cancer 1976;34:655-659.
7. Henle W, Ho JH, Henle G, Kwan HC. Antibodies to Epstein-Barr virus-related antigens in nasopharyngeal carcinoma. Comparison of active cases with long-term survivors. J Natl Cancer Inst 1973;51:361-369.
8. Henle W, Ho JH, Henle G, Chau JC, Kwan HC. Nasopharyngeal carcinoma: significance of changes in Epstein-Barr virus-related antibody positives following therapy. Int J Cancer 1977;20:663-672.
9. Ho S, Teo P, Kwan WH, Choi P, Tjong J, Johnson PJ. Staging and IgA-VCA titre in patients with nasopharyngeal carcinoma: changes over a 12-year period. Oral Oncol 1998;34:491-495.
10. Chien YC, Chen JY, Liu MY, et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 2001;345:1877-1882.
11. Zeng Y, Zhang LG, Li HY, et al. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou city, China. Int J Cancer 1982;29:139-141.
12. Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999;59:1188-1191.
13. Tong JH, Tsang RK, Lo KW, et al. Quantitative Epstein. Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma. Clin Cancer Res 2002;8:2612-2619.